^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Published date:
11/06/2019
Excerpt:
Certain cytogenetic features correlated with greater sensitivity to Rux+Ven (e.g. t(9;11) - MLL-rearrangement) or decreased sensitivity (e.g. t(15;17) - PML-RARA or monosomy 5/del 5q).
DOI:
https://doi.org/10.1182/blood-2019-126020